Tuesday, July 1, 2025 7/1/2025

Cell type-specific function of LMNA during myocardial stress in the development of cardiomyopathy

Award Number: R01HL150019
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/15/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Cell type-specific function of LMNA during myocardial stress in the development of cardiomyopathy - Project Summary Mutations in the LMNA gene encoding lamin A/C cause a diverse group of human diseases termed laminopathies. The most prevalent laminopathy is dilated cardiomyopathy (herein referred to as LMNA cardiomyopathy). Despite recent progress in understanding the diverse cellular function of lamin A/C, what pathogenic mechanisms are triggered by LMNA mutations in specific cell types of the myocardium and how they are integrated at the tissue level to produce a cardiac phenotype is largely unknown. The prevailing view is that LMNA mutations cause a myriad of cellular defects that all contribute to the disease but this broad assertion has never been rigorously tested. Our preliminary data suggest that lamin A/C play a crucial role in cardiac fibroblasts (CF) function in fibrosis and the onset and/or the pathogenicity of LMNA cardiomyopathy is more severe if the lamin A/C function is selectively impaired in cardiomyocytes (CM). In vivo Lmna deletion specifically in adult CMs caused rapid onset of fibrosis and severe cardiac dysfunction. In contrast, Lmna deletion in CFs displayed no immediate cardiac pathology. Surprisingly, relative to CM-deletion alone, concomitant deletion of Lmna in CMs and CFs resulted in lesser fibrosis and pathological remodeling. These results suggest that lamin A/C in CFs play a crucial role in the development of fibrosis/cardiac remodeling and that these pathological features underlie the disease progression and severity in response to CM stress. At the molecular level, we implicate increased matrix stiffness from fibrosis contribute to CM expression of ER stress markers and MED25, which is a member of the Mediator complex identified as a regulator of ER stress responses. Taken together, our results suggest lamin A/C-depleted CFs mediate a brake on cardiomyopathy development and interactions between CFs and CMs are important determinants of the rate of progression and the severity of LMNA cardiomyopathy. Based on our preliminary data, we hypothesize that lamin A/C contribute to the pathogenesis of LMNA cardiomyopathy in an opposing manner depending on the cell type; lamin A/C promote CF-mediated fibrosis in response to myocardial stress while in parallel protect CMs from ER stress and cell damage. To test our hypothesis, Aim1 will determine whether lamin A/C regulation of CF function underlies the rate and the severity of disease progression. We will elucidate the putative mechanisms by which Lmna deletion impairs CF function in the stressed myocardium. In Aim2, we will determine how the mechanical component of fibrosis contributes to CM damage caused by LMNA mutations. Under varying matrix stiffness, we will delineate the mechanism underlying CM damage caused by LMNA mutations and contextualize the involvement of ER stress. These aims will not only lead to a better understanding of lamin A/C function in CFs, CMs, and their crosstalk in disease pathogenesis but may also enable the development of new therapies for LMNA cardiomyopathy and perhaps other forms of cardiomyopathies in which fibrosis is integral to their pathogenesis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	4	1/15/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $390,000 )
2023	2023	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	4	2/23/2023	NON-COMPETING CONTINUATION	$390,000
														Subtotal = $390,000

Issue Date FY: 2022 ( Subtotal = $392,201 )
2022	2022	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	3	2/7/2022	NON-COMPETING CONTINUATION	$352,980
2022	2022	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	001	3	6/29/2022	NON-COMPETING CONTINUATION	$39,221
														Subtotal = $392,201

Issue Date FY: 2021 ( Subtotal = $392,172 )
2021	2021	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	2	2/21/2021	NON-COMPETING CONTINUATION	$392,172
														Subtotal = $392,172

Issue Date FY: 2020 ( Subtotal = $406,144 )
2020	2020	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	1	3/12/2020	NEW	$406,144
														Subtotal = $406,144

Grand Total All Awards = $1,580,517

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cell type-specific function of LMNA during myocardial stress in the development of cardiomyopathy

Award Number: R01HL150019

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/15/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer